Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Camp For Children With Hearing Loss And Their Families Offers Weekend Of Fun
The House Ear Institute, HEI, established Family Camp 24 years ago as a comfortable, open forum where parents raising a child with hearing loss could share their experiences and exchange information and varying philosophies with one another.
generic viagra online
Drug Crimes In Canada Cause Continuing Problems For Small Communities
The Narconon drug rehab program has noticed a trend of many drug addicts being involved with drug related charges due to their addiction. "You can have the everyday functioning addict who is battling a drug addiction, and just one day gets caught by police for possession of a small amount," comments Nick Hayes, a representative of Narconon Trois-Rivieres. "This is an all too common situation for many people who are involved in a drug addiction." More people are using illicit drugs in Canada, in fact Trois-Rivieres, Quebec, Canada, where the Narconon drug rehab program is located, is one of the leading cities in Canada for drug crimes. "There are so many youth in Trois-Rivieres who are addicted to different drugs like speed, ecstasy, marijuana, and even cocaine. These teens get caught up with the law and start heading down the wrong path at a very young age," says Nick.
News of the day
Ambulance Service Makes Progress Against Tougher Response Time Targets
Ambulance Trusts across the country have significantly reduced the time taken to reach patients, according to data published today by the NHS Information Centre. 74.3% of the most urgent calls (Category A) were responded to in less than 8 minutes from a call being received.
Oncology

Argenta Discovery And Porsolt Join Forces To Provide Fully-integrated CNS And Pain Contract Drug Discovery Services

Argenta Discovery and Porsolt announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for- service basis. The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination. Both companies bring a wealth of "Big Pharma" industry based experience and know-how in CNS and pain research. This alliance will leverage those key skills for its partners to ensure the rapid generation of high quality development candidates. Dr. Christopher Ashton, CEO of Argenta said, "Argenta has undertaken many successful medicinal chemistry-driven CNS and pain contract drug discovery research projects, but we have been looking at ways of enhancing our capabilities in these important therapeutic areas. Argenta has partnered with Porsolt to provide clients with dedicated access to specialist CNS and pain models and expertise, offered by a world leader in the field. We have several ongoing contract research programmes in these therapeutic areas and a number of projects in the pipeline which are likely to benefit from Porsolt"s support and know-how. This alliance will enable Argenta to offer an even better integrated drug discovery service in the future. We are looking forward to working with Porsolt." Dr Mark Duxon, CEO of Porsolt added, "Porsolt is delighted to be entering into a partnership with Argenta to deliver full lead optimisation drug discovery on a contract research basis. Porsolt have recently announced a significant laboratory expansion in France and the Argenta partnership fits with our strategy of offering a diverse array of deal structure opportunities to suit the broad range of our clients" needs. Indeed, our increased business flexibility is entirely complementary to our client-oriented scientific expertise. Porsolt has always sought to deliver quality scientific solutions tailored to client needs. In this respect, we believe we have found a like minded partner in Argenta". Where there is a client need for outsourcing fully integrated drug discovery programmes for CNS and pain targets, Argenta and Porsolt offer a seamless drug discovery platform to the pharmaceutical industry, from hit identification to drug candidate selection. Should a client not be interested in a solution of this nature, both Porsolt and Argenta will continue to operate independently, offering their stand-alone contract research services spanning all therapeutic areas and drug target classes. Porsolt & Partners Pharmacology Argenta Discovery Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009